头颈部鳞状细胞癌患者骨骼肌质量与顺铂放化疗后感觉神经性听力损失的相关性
本研究为回顾性队列研究,纳入81例接受顺铂放化疗的头颈部鳞状细胞癌患者,通过治疗前CT评估腰大肌骨骼肌指数(LSMI),并在基线和随访时行纯音测听评估治疗相关感觉神经性听力损失。线性混合模型显示,低LSMI与对言语感知关键的纯音频率(1、2、4 kHz平均值)上治疗相关感觉神经性听力损失增加显著相关(p=0.048)。结论认为低LSMI患者在接受顺铂放化疗后感觉神经性听力损失更重。
要点
- 治疗前低腰大肌骨骼肌指数与顺铂放化疗后感觉神经性听力损失增加显著相关(p=0.048)。
- 关联见于对言语感知关键的纯音频率(1、2、4 kHz平均值)。
- 研究为回顾性队列,纳入81例头颈部鳞状细胞癌患者。
核心结论
- 头颈部鳞状细胞癌患者中,低腰大肌骨骼肌指数者接受顺铂放化疗后治疗相关感觉神经性听力损失更重。
研究设计与样本
- 回顾性队列研究,纳入81例接受顺铂放化疗的头颈部鳞状细胞癌患者。
- 治疗前采用常规CT评估腰大肌骨骼肌指数(LSMI)。
- 基线和随访时行纯音测听评估治疗相关感觉神经性听力损失。
- 采用线性混合模型分析连续变量LSMI与感觉神经性听力损失之间的关联。
主要发现
- 低LSMI与对言语感知关键的纯音频率(1、2、4 kHz平均值)上治疗相关感觉神经性听力损失增加显著相关(p=0.048)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin-based chemoradiotherapy (CRT) frequently experience irreversible sensorineural hearing loss (SNHL). Patients with low lumbar skeletal muscle index (LSMI) may experience higher serum peak dosages of cisplatin. This study investigated whether pre-treatment low LSMI is associated with increased SNHL upon cisplatin-based CRT. MATERIALS AND METHODS: LSMI was assessed using routine pre-treatment CT scans. Pure tone audiometry was performed at baseline and at follow-up to assess treatment-related SNHL. Linear mixed models were used to reveal a potential association between the continuous variable LSMI and SNHL. RESULTS: This retrospective cohort study included 81 patients and found a significant association between low LSMI and increased treatment-related SNHL at pure tone frequencies vital for the perception of speech (averaged of 1, 2, and 4 kHz) (p = 0.048). CONCLUSIONS: HNSCC patients with low LSMI suffer increased treatment-related SNHL upon cisplatin-based CRT.
引用
- Schaeffers AWMA, Burger AVM, Duinkerken CW, et al. The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma. Head Neck. 2024. PMID: 39096016. doi:10.1002/hed.27907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。